Dan Roden
Faculty Member
Last active: 3/24/2020

Cardiovascular pharmacogenomics.

Roden DM, Johnson JA, Kimmel SE, Krauss RM, Medina MW, Shuldiner A, Wilke RA
Circ Res. 2011 109 (7): 807-20

PMID: 21921273 · PMCID: PMC3201825 · DOI:10.1161/CIRCRESAHA.110.230995

Patients vary in their responses to drug therapy, and some of that variability is genetically determined. This review outlines general approaches used to identify genetic variation that influences drug response. Examples from specific therapeutic areas are presented, such as cholesterol management, arrhythmias, heart failure, hypertension, warfarin anticoagulation, and antiplatelet agents. A brief view of potential pathways to implementation is presented.

MeSH Terms (12)

Biological Transport Biotransformation Cardiovascular Agents Cardiovascular Diseases Drug Dosage Calculations Genetic Variation Humans Patient Selection Pharmacogenetics Precision Medicine Risk Assessment Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: